AU2002256991A1 - Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein - Google Patents

Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein

Info

Publication number
AU2002256991A1
AU2002256991A1 AU2002256991A AU2002256991A AU2002256991A1 AU 2002256991 A1 AU2002256991 A1 AU 2002256991A1 AU 2002256991 A AU2002256991 A AU 2002256991A AU 2002256991 A AU2002256991 A AU 2002256991A AU 2002256991 A1 AU2002256991 A1 AU 2002256991A1
Authority
AU
Australia
Prior art keywords
xanthenes
viral replication
nucleocapsid protein
inhibiting viral
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002256991A
Inventor
Robert J. Fisher
Judy A. Mikovits
Robert H. Shoemaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GOVERNMENT OF United States, HEALT, Secretary of, Department of
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2002256991A1 publication Critical patent/AU2002256991A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
AU2002256991A 2001-02-05 2002-02-05 Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein Abandoned AU2002256991A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26666501P 2001-02-05 2001-02-05
US60/266,665 2001-02-05
PCT/US2002/003592 WO2002062333A1 (en) 2001-02-05 2002-02-05 Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein

Publications (1)

Publication Number Publication Date
AU2002256991A1 true AU2002256991A1 (en) 2002-08-19

Family

ID=23015497

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256991A Abandoned AU2002256991A1 (en) 2001-02-05 2002-02-05 Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein

Country Status (2)

Country Link
AU (1) AU2002256991A1 (en)
WO (1) WO2002062333A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572828B2 (en) 2002-10-08 2009-08-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid
WO2007048042A2 (en) * 2005-10-21 2007-04-26 University Of Alabama At Birmingham Small molecule inhibitors of hiv-1 capsid assembly
US8530675B2 (en) 2009-09-18 2013-09-10 Provectus Pharmaceuticals, Inc. Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (rose bengal) and related xanthenes
US9273022B2 (en) 2009-09-18 2016-03-01 Provectus Pharmaceuticals, Inc. Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′, 4′, 5′7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (Rose Bengal) and related xanthenes
CN115916343A (en) * 2020-03-26 2023-04-04 普罗维克图斯药品技术公司 New use of halogenated xanthenes in oncology and virology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2678997A (en) * 1996-04-19 1997-11-12 Lexigen Pharmaceuticals Corp. Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response
US6140338A (en) * 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists

Also Published As

Publication number Publication date
WO2002062333A9 (en) 2003-01-30
WO2002062333A8 (en) 2002-10-03
WO2002062333A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
AU2001244188A1 (en) Medicaments against viral diseases
EG24026A (en) Respiratory syncytial virus replication inhibitors
AU2002258990A1 (en) Improvements in ablation therapy
AU2001248673A1 (en) Nasal inhaler
HK1045997A1 (en) Respiratory syncytial virus replication inhibitors
AU2002223028A1 (en) Inhaler
HK1091126A1 (en) Methods for inhibiting viral replication in vivo
AU2003206862A1 (en) Hepatitis b vaccines
AU2003256919A1 (en) Virus induced gene silencing in plants
AU2001268986A1 (en) Method for inducing viral resistance in plants
AU2001286721A1 (en) Human interleukin-four induced protein
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU2002256991A1 (en) Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein
AU5032501A (en) Use of cationic protein hydrolysates
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2001267239A1 (en) Viral phospholipase a2 enzymes, anti-viral agents and methods of use
AU2003251356A1 (en) Viral marker
AU2001257427A1 (en) Rna metabolism proteins
WO2002083858A8 (en) Methods to inhibit viral replication
AU2002252773A1 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
AU2002230744A1 (en) Tapered microkeratome head
AU2002236065A1 (en) Papillomavirus vaccines
AU2002350181A1 (en) Compositions and methods for viral delivery
AU2002224845A1 (en) Viral expression system
AU2002323085A1 (en) Inhibition of viral replication by targeting rna-dna complexes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase